Schizophrenia Epidemiology Analysis and Forecast, 2021-2031

In the 7MM, the total prevalent cases of schizophrenia were 5,121,015 in 2021. The cases are expected to grow at an AGR of less than 1% during the period 2021-2031. Schizophrenia is a chronic and debilitating mental illness, characterized by delusions, hallucinations, disorganized speech, trouble with thinking, and a lack of motivation. Schizophrenia is among the most disabling and economically catastrophic medical disorders, ranked by the World Health Organization (WHO) as one of the top 10 illnesses contributing to the global burden of disease. The disorder is characterized by the presence of both positive and negative symptoms.

For more insights, download a free report sample

Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia

The key age segments in the 12-month diagnosed prevalent cases of schizophrenia are 13-17 years, 18-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and more than 80. In 2021, for the 7MM combined, adults ages 50–59 years contributed the highest proportion of the 12-month diagnosed prevalent cases of schizophrenia.

Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia

For more key age segment insights, download a free report sample

COVID-19 Impact in the Schizophrenia Epidemiology Market

The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences as global healthcare systems have been redirected to focus on fighting the pandemic. The impact of the COVID-19 pandemic may include a shortage of medical staff, decreased access to treatment, a delay in diagnosis, decreased survival, and an increase in disease incidence related to coronavirus infections. The COVID-19 pandemic is having a critical impact on healthcare systems globally, as well as on mental health in the general population. People living with schizophrenia are at an increased risk of COVID-19 and present worse COVID-19-related outcomes, including mortality. They show low levels of information and concern regarding the possibility of contagion and infection but presented substantially stable levels of psychotic symptoms and even increased subjective well-being during the pandemic.

Market report overview

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical trends for schizophrenia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides a 10-year epidemiological forecast for 12‒month total prevalent cases and 12‒month diagnosed prevalent cases of schizophrenia.
• The 12‒month diagnosed prevalent cases of schizophrenia are further segmented by age (13–17 years, 18–19 years, 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) in these markets. The model accompanying this report also provides the 12-month total prevalent cases and 12-month diagnosed prevalent cases of schizophrenia and the listed segments. The schizophrenia epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The schizophrenia epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
• Quantify patient populations in the global schizophrenia market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for schizophrenia therapeutics in each of the markets covered.
• Enable to understand the magnitude of 12-month diagnosed prevalence of schizophrenia.